Medfield, MA – According to filings with the U.S. Securities and Exchange Commission, Kinaset Therapeutics is raising $41,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Robert Clarke played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kinaset Therapeutics
Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. Our lead clinical candidate, KN-002, is a novel and non-invasive anti-inflammatory to treat all patients with severe asthma. With our founding investors, 5 AM Ventures, Atlas Venture and Gimv, we are pursuing a patient-focused approach to build a leading respiratory therapeutics company. Kinaset is led by a team with significant respiratory drug development experience and supported by leading scientific and clinical advisors in the field.

To learn more about Kinaset Therapeutics, visit http://www.kinasettherapeutics.com/

Contact:
Robert Clarke, Chief Executive Officer
508-858-5810
robert@kinasettherapeutics.com
https://www.linkedin.com/in/robert-clarke-aa3b524/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved